RxDoctor Payments Data

Kausik Umanath, MD

Nephrology · Detroit, MINPI 1861514259

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $58,931 of the $85,235 with a category attached, or 69.1%. AstraZeneca accounts for 83.3% of it on its own, with 5 other manufacturers making up the rest. Among nephrology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$85,235in general payments, 2019–2025

Across 90 payments — averaging $947.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$71K
  • Astrazeneca UK Limited$11K
  • Boehringer Ingelheim International GmbH$1K
  • Bayer$1K
  • Vifor Pharma, Inc.$118
  • Novo Nordisk$105
$329,814in research payments, 2019–2025

Across 179 payments — averaging $1842.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$159K
  • Novo Nordisk AS$92K
  • GSK$37K
  • Bayer$21K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$12K
  • Eli Lilly$6K
  • plus $3K from 2 others

What the payments were for

  • Consulting fees$58,93169%
  • Travel & lodging$24,48029%
  • Food & beverage$1,8242%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,235 in reported general payments places this provider in the 95th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$62,827
Medicare patients
211
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate18$19,372
Calcium Acetate51$2,138
Nifedipine ErNifedipine17$1,153
Losartan Potassium50$275
Amlodipine Besylate63$246
Chlorthalidone29$242
Carvedilol28$230
Hydralazine Hcl16$218
Furosemide15$82
Lisinopril12$69
Hydrochlorothiazide19$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$71,034$19,37218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 325 nephrology providers in Michigan.

Other nephrology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →